ArticleVirology2014
Biodistribution, pharmacokinetics, and blood compatibility of native and PEGylated tobacco mosaic virus nano-rods and -spheres in mice.
Article in Virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 178 citations in OpenAlex.
- Immunofunctions of Protein and Carbohydrate Assemblies Modulated by Structures Acrossing Scales as Biomaterials.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Targeting Cancer Cell Fate: Apoptosis, Autophagy, and Gold Nanoparticles in Treatment Strategies.Current issues in molecular biology · 2025Review
- A replicon-based COVID-19 vaccine candidate delivered by tobacco mosaic virus-like particles.Vaccine · 2025Article
- Review
- Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.Bioengineering (Basel, Switzerland) · 2024Review
- Assessment of a Structurally Modified Alternanthera Mosaic Plant Virus as a Delivery System for Sarcoma Cells.Viruses · 2024Article
- Magnetically Induced Thermal Effects on Tobacco Mosaic Virus-Based Nanocomposites for a Programmed Disassembly of Protein Cages.ACS applied bio materials · 2024Article
- Novel Universal Recombinant Rotavirus A Vaccine Candidate: Evaluation of Immunological Properties.Viruses · 2024Article
- Pharmacology of a Plant Virus Immunotherapy Candidate for Peritoneal Metastatic Ovarian Cancer.ACS pharmacology & translational science · 2024Article
- A detailed insight of the tumor targeting using nanocarrier drug delivery system.Drug delivery · 2023Review
- Review
- Preparation and Biological Properties of Oligonucleotide-Functionalized Virus-like Particles.Biomacromolecules · 2023Article
- Cisplatin-Loaded Tobacco Mosaic Virus for Ovarian Cancer Treatment.Biomacromolecules · 2022Article
- Review
- Polymeric Nanotubes as Drug Delivery Vectors─Comparison of Covalently and Supramolecularly Assembled Constructs.Biomacromolecules · 2022Article
- Structurally Modified Plant Viruses and Bacteriophages with Helical Structure. Properties and Applications.Biochemistry. Biokhimiia · 2022Review
- Designing StablePharmaceutics · 2022Article
- Drug-Dependent Morphological Transitions in Spherical and Worm-Like Polymeric Micelles Define Stability and Pharmacological Performance of Micellar Drugs.Small (Weinheim an der Bergstrasse, Germany) · 2022Article
- New formulation of a recombinant anthrax vaccine stabilised with structurally modified plant viruses.Frontiers in microbiology · 2022Article
- Production of Potyvirus-Derived Nanoparticles Decorated with a Nanobody in Biofactory Plants.Frontiers in bioengineering and biotechnology · 2022Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Understanding the pharmacokinetics, blood compatibility, biodistribution and clearance properties of nanoparticles is of great importance to their translation to clinical application. In this paper we report the biodistribution and pharmacokinetic properties of tobacco mosaic virus (TMV) in the forms of 300×18nm(2) rods and 54nm-sized spheres. The availability of rods and spheres made of the same protein provides a unique scaffold to study the effect of nanoparticle shape on in vivo fate. For enhanced biocompatibility, we also considered a PEGylated formulation. Overall, the versions of nanoparticles exhibited comparable in vivo profiles; a few differences were noted: data indicate that rods circulate longer than spheres, illustrating the effect that shape plays on circulation. Also, PEGylation increased circulation times. We found that macrophages in the liver and spleen cleared the TMV rods and spheres from circulation. In the spleen, the viral nanoparticles trafficked through the marginal zone before eventually co-localizing in B-cell follicles. TMV rods and spheres were cleared from the liver and spleen within days with no apparent changes in histology, it was noted that spheres are more rapidly cleared from tissues compared to rods. Further, blood biocompatibility was supported, as none of the formulations induced clotting or hemolysis. This work lays the foundation for further application and tailoring of TMV for biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.